Exciting immunotherapies for lymphoma presented at ASH 2019
Click Here to Manage Email Alerts
ORLANDO — Joshua Brody, MD, director of the lymphoma immunotherapy program, Icahn School of Medicine at Mount Sinai, spoke about exciting data on novel immunotherapies for different types of lymphoma presented at ASH Annual Meeting & Exposition.
Along with promising results from a large CAR-T cell trial for mantle cell lymphoma, Brody discussed the effectiveness of bispecific antibodies for diffuse large B-cell lymphoma.
“I think these agents can become FDA approved in a year from now, or sometime soon, so we need to learn how to use them – both as effectively as possible and as safely as possible. That’s some of what we’re learning here now,” he said.
Disclosure: Brody reports no relevant financial disclosures.